Arkin Capital
Also known as Arkin Holdings
Israeli investment group (formerly Arkin Holdings) of Mori Arkin, with Health, Equity, Tech and Real Estate arms; over $2B across 12 funds (2026), partly backed by Israeli institutions.
USEFUL FOR Founders · Business owners seeking a long-term partner · Co-investors
Israeli investment group (formerly Arkin Holdings) in whose funds Mori Arkin invests. Arkin Bio (Arkin Bio Ventures, Arkin Bio Capital) is its life-sciences arm; its funds also take Israeli institutional capital.
Family & background
- FAMILY
- Arkin (Mori Arkin)
- HEADQUARTERS
- Israel
- AUM
- $2B (2026)
- OUTSIDE CAPITAL
- Yes — also manages others' money
Investment approach
- GEOGRAPHY
- Global
- STAGES
- Series AGrowth
- ROUTES
- Companies (own capital)
- STRATEGIES
- Venture capitalHedge fundsDirect investmentsReal estatePublic equities
- LATEST DEAL
- Bionyra Pharma (Series A) · Jun 2026
Overview
Arkin Capital, earlier known as Arkin Holdings, is an Israeli investment group; Globes reported in 2021 that Mori Arkin himself invested in its $270 million crossover fund alongside Israeli institutions. It invests through four arms (Arkin Health, Arkin Equity, Arkin Tech and Arkin Real Estate) and reported more than $2 billion in assets across 12 funds in January 2026, including venture funds, hedge funds and direct investments. Its life-sciences arm Arkin Bio runs Arkin Bio Ventures (early stage; funds I in 2016, II in 2020, III in 2026) and Arkin Bio Capital (late stage), with over $600 million in biotech assets. Arkin Bio Ventures III ($100M) is backed by Phoenix Insurance, Clal Insurance and Amitim pension funds alongside a significant commitment from Arkin Capital itself.
Holdings & investments (6)
- HI-Bio (Human Immunology Biosciences)NOTABLEBiotech & Life Sciences
- cCAM BiotherapeuticsNOTABLEBiotech & Life Sciences
- Bionyra PharmaBiotech & Life Sciences · since 2026
- UroGen PharmaBiotech & Life Sciences
- Keros TherapeuticsBiotech & Life Sciences
- HealthTech
People
Frequently asked questions
Arkin Capital is a family holding based in Israel.
Arkin Capital invests on behalf of the Arkin (Mori Arkin) family.
Arkin Capital invests its own capital into companies. Its stated asset mix includes venture capital, hedge funds, direct investments, real estate and public equities.
Arkin Capital invests at Series A and Growth stages in Biotech & Life Sciences, HealthTech and Real Estate & PropTech.
Key people at Arkin Capital include Pini Orbach (Managing Partner, Arkin Bio) and Avital Adler (Principal, Arkin Bio).
Arkin Capital's holdings and investments include HI-Bio (Human Immunology Biosciences), cCAM Biotherapeutics, Bionyra Pharma, UroGen Pharma, Keros Therapeutics and Eleos.
The most recent publicly reported investment by Arkin Capital is Bionyra Pharma (Series A), announced in Jun 2026.
Yes. Arkin Capital manages capital from outside investors.